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	 A	sensitive,	rapid,	selective	and	accurate	liquid	chromatography	coupled	to	quadrupole
tandem	 mass	 spectrometry	 (LC‐MS/MS)	 method	 was	 developed	 for	 simultaneous
identification	 and	 quantification	 of	 tamsulosin	 and	 finasteride	 in	 bulk	 and	 in	 their
combined	dosage	form.	Chromatography	was	performed	on	a	Hypersil	gold	50	mm	×	2
mm	(1.9	μm)	column,	using	acetonitrile:ammonium	acetate	(90:10,	v:v)	pH	=	3.5	as	the
mobile	phase.	Protonated	ions	formed	by	a	turbo	ion‐spray	in	positive	mode	were	used
to	detect	the	analytes	as	well	as	the	internal	standard	(IS).	MS/MS	detection	was	carried
out	by	monitoring	the	fragmentation	of	408.74	→	227.29	(m/z),	373.11	→	304.96	(m/z)
and	 255.75	 →	 166.15	 (m/z)	 for	 tamsulosin,	 finasteride	 and	 diphenhydramine	 (IS),
respectively,	on	a	triple	quadrupole	mass	spectrometer.	The	linearity	was	obtained	over
the	 concentration	 range	 of	 1.6‐40.0	 ng/mL	 for	 tamsulosin	 and	 20.0‐500.0	 ng/mL	 for
finasteride	with	a	lower	limit	of	detection	of	0.5	ng/mL	and	5.0	ng/mL	for	the	two	drugs,
respectively.	 The	 proposed	 method	 was	 successfully	 applied	 to	 tamsulosin	 and
finasteride	 determination	 in	 pharmaceutical	 dosage	 form.	 The	 results	 obtained	 were
statistically	 analyzed	 and	 compared	 with	 those	 of	 reference	 ones;	 in	 addition,	 the
method	 was	 validated	 according	 to	 USP	 34	 recommendations.	 The	 simplicity	 and
sensitivity	of	this	method	allows	its	use	in	the	quality	control	of	the	cited	drugs	and	can
be	extended	for	routine	analysis	of	the	drugs	in	their	pharmaceutical	preparations.	
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1.	Introduction	
	
Tamsulosin	 (TAM)	 is	 a	 sulfamoylphenethylamine	
derivative	 (Figure	 1)	 commonly	 used	 to	 treat	 signs	 and	
symptoms	of	benign	prostatic	hyperplasia	(BPH)	[1,2].	TAM	is	a	
selective,	 potent	 and	 competitive	 α1‐adrenoceptor	 antagonist	
[3,4].	 The	USP	has	described	a	potentiometric	method	 for	 the	
analysis	of	TAM	[5],	besides;	various	analytical	techniques	have	
been	reported	 for	 the	determination	of	TAM	 in	bulk,	pharma‐
ceutical	formulations	and	biological	samples.	These	techniques	
include	 HPLC	 [6‐9],	 stability	 indicating	 HPLC	 [10],	 stability	
indicating	HPTLC	[11],	LC‐MS/MS	[12‐14],	potentiometry	[15],	
voltametry	 [16],	 capillary	 electrophoresis	 [17],	 spectrofluori‐
metry	[18],	UV	[19]	and	visible	spectrophotometry	[20].	
Finasteride	 (FIN),	N‐(1,1‐dimethylethyl)‐3‐oxo‐(5α,17β)‐4‐
azaandrost‐1‐ene‐17‐carboxamide	 (Figure	 1),	 is	 a	 synthetic	
antiandrogen	which	acts	by	inhibiting	type	II	5‐α	reductase,	the	
enzyme	 that	 converts	 testosterone	 to	 dihydrotestosterone	
(DHT).	It	is	used	as	a	treatment	in	benign	prostatic	hyperplasia	
in	low	doses,	and	prostate	cancer	in	higher	doses.	It	is	also	used	
for	treatment	of	male‐pattern	baldness	in	men	at	a	dose	of	1	mg	
daily	 [21].	 In	 addition	 to	 the	 HPLC	 method	 described	 by	 the	
USP	 [5],	 several	 methods	 for	 determination	 of	 FIN	 in	 bulk,	
pharmaceutical	formulations	and	biological	samples	have	been	
developed.	 These	 methods	 include	 HPLC	 [22],	 polarography	
[23]	and	LC‐MS	[24,25].	
There	are	 few	published	methods	 for	 the	high	 throughput	
determination	 of	 TAM	 and	 FIN	 in	 bulk	 and	 combined	 dosage	
forms	 previously	 reported	 using	 HPLC	 and	 TLC	 methods	
[26,27].	
The	 lack	 of	 LC‐MS/MS	 methods	 for	 the	 simultaneous	
analysis	 of	 both	 TAM	 and	 FIN	 has	motivated	 us	 to	 develop	 a	
simple,	 sensitive	 and	 validated	 LC‐MS/MS	 method	 for	 their	
determination.	 For	 best	 detection	 up	 to	 nano‐gram	 level	 of	
TAM	 and	 FIN;	 the	 chromatographic	 conditions	 and	 the	 mass	
spectrometric	 parameters	 were	 thoroughly	 studied	 and	
adjusted.	The	method	was	subsequently	used	to	determine	the	
concentration	of	the	drugs	in	 laboratory	prepared	mixtures	as	
well	 as	 in	 combined	 dosage	 forms.	 Our	 experimental	 results	
were	 statistically	 analyzed	 and	 compared	 with	 those	 of	
reference	ones.	
	
2.	Experimental	
	
2.1.	Materials	and	reagents	
	
Tamsulosin	HCl	was	kindly	supplied	from	Osmopharm	S.	A.,	
Bedano,	Switzerland,	while,	finasteride	and	diphenhydramine		
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Table	1.	Tandem	mass	spectrometric	parameters	of	tamsulosin,	finasteride	and	diphenhydramine.	
Parameter	 Value	
Turbo	ion	spray	temperature	(°C)	 400
Capillary	temperature	(°C)	 270
Sheath	gas	(psi)	 20	
Auxillary	gas	(psi)	 2	
Ion	spray	voltage	(V)	 3600	
Capillary	offset	 35	
Tamsulosin Finasteride Diphenhydramine	(IS)
Collision	energy	(V)	 23 27 25	
SRM	transition	(m/z)	 408.74	/	227.29 373.11 /	304.96 255.75	/	166.15	
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Figure	1.	Chemical	structures	of	tamsulosin	(a),	finasteride	(b)	and	diphenhydramine	as	IS	(c).	
	
	
	
(IS)	 were	 purchased	 from	 Sigma	 Pharmaceutical	 Industries,	
Steinheim,	Germany.	Their	purities	were	certified	and	analyzed	
by	 reference	methods	and	were	 found	 to	be	 99.54%	 for	TAM	
[26]	 and	 99.86%	 for	 FIN	 [5].	 They	 were	 used	 as	 provided.	
Urimax	 F	 tablets	 (0.4	 mg	 TAM	 +	 5	 mg	 FIN)	 Cipla	
Pharmaceutical	Ltd.,	Mumbai,	 India.	All	solvents	and	materials	
were	 of	 HPLC	 grade.	 Methanol	 was	 purchased	 from	 Fischer	
Scientific	 UK	 Ltd,	 Loughborough,	UK.	 Acetonitrile	 and	
Ammonium	 acetate	 were	 purchased	 from	 Merck,	 Darmstadt,	
Germany.	Deionized	water	(Purelab	flex,	ELGA)	was	used.	
	
2.2.	Instrumentation	
	
The	analysis	was	performed	using	a	TSQ	Quantum	Access	
MAX	 triple	 stage	 quadrupole	 mass	 spectrometer,	
Thermoscientific,	 New	 York,	 USA,	 equipped	 with	 an	
electrospray	ionization	(ESI)	source.	Xcalibur	software	version	
2.2	 was	 used	 to	 control	 the	 LC‐MS/MS	 system,	 collect	 and	
analyse	 the	 data.	 The	 HPLC	 system	 consisted	 of	 an	 Accela	 U‐
HPLC	 with	 Accela	 1250	 quaternary	 pump	 and	 Accela	 open	
autosampler,	New	York,	USA	operated	at	15	°C. 	
	
2.3.	Mass	spectrometric	conditions	
	
The	 positive‐ion	 mass	 spectrometric	 detection	 method	
utilised	electrospray	ionization	and	single	reaction	monitoring	
(SRM)	 mode.	 The	 optimized	 parameters	 are	 summarized	 in	
Table	1.		
	
2.4.	Chromatographic	conditions	
	
Chromatographic	 separation	 was	 performed	 on	 Hypersil‐
Gold	 column	 (C18‐bonded	 ultrapure	 silica	 based	 column)	 50	
mm	×	2.0	mm	(1.9	μm)	from	Thermoscientific,	New	York,	USA.	
Elution	was	performed	at	 room	temperature	using	 the	mobile	
phase	10	mM	ammonium	acetate:acetonitrile	(10:90,	v:v)	(pH	=	
3.5).	The	LC	system	was	operated	isocratically	at	250	μL/min.	
The	 injection	 volume	was	 10	 µL.	 The	 total	 run	 time	 for	 each	
sample	was	3	min.	
	
2.5.	Standard	solutions	
	
Stock	 solutions	 (0.1	 mg/mL)	 of	 TAM,	 FIN	 and	 IS	 were	
separately	 prepared	 in	 100	mL	 volumetric	 flasks	 in	methanol	
while	the	working	standard	solutions	were	prepared	by	further	
dilution	of	the	corresponding	stock	solutions	with	methanol.	All	
stock	solutions	were	kept	at	‐20	°C	until	use,	whilst	the	working	
solutions	were	kept	at	4	°C	and	discarded	within	30	days.		
	
2.6.	Procedures	
	
2.6.1.	Calibration	curves		
	
Six	 standard	 solutions	 of	 each	 drug	 were	 prepared	 in	
concentration	 ranges	1.6‐40.0	ng/mL	 for	TAM	and	20.0‐500.0	
ng/mL	 for	 FIN	with	 the	 addition	 of	 40	 ng/mL	 of	 IS	 on	 every	
standard	solution.	A	10	μL	aliquot	of	each	solution	was	injected	
onto	 the	 LC‐MS	 system.	 Two	 calibration	 curves	 were	
established	separately	for	each	drug.	The	calibration	curve	was	
constructed	by	plotting	of	the	peak	area	ratios	of	each	analyte	
to	IS	obtained	against	the	corresponding	concentrations.	
	
2.6.2.	Laboratory	prepared	mixtures	
	
Binary	laboratory	prepared	mixtures	of	TAM	and	FIN	were	
prepared	by	mixing	their	working	solutions	in	different	ratios,	
then	 40.0	 ng/mL	 of	 IS	 was	 added.	 A	 10	 μL	 aliquot	 of	 each	
solution	 was	 injected	 onto	 the	 LC‐MS	 system,	 and	 the	
procedure	was	continued	as	stated	under	calibration	curves.		
	
2.6.3.	Dosage	form		
	
For	analysis	of	the	pharmaceutical	dosage	form,	10	tablets	
were	 pulverized	 well;	 an	 accurate	 amount	 of	 the	 powdered	
Mohamed	et	al.	/	European	Journal	of	Chemistry	5	(1)	(2014)	181‐185	 183	
 
tablets	 equivalent	 to	 12.5	mg	 of	 FIN	 and	 1.0	mg	 of	 TAM,	was	
weighed	 and	 transferred	 into	 100	 mL	 volumetric	 flask	 and	
dissolved	 in	 methanol,	 then	 the	 procedure	 was	 continued	 as	
stated	under	calibration	curves.	
	
3.	Results	and	discussion	
	
For	optimum	detection	up	to	nano‐gram	level	of	TAM,	FIN	
and	the	IS	it	was	necessary	to	adjust	both	the	chromatographic	
conditions	 and	 the	mass	 spectrometric	 parameters.	 Precursor	
ions	and	product	 ions	were	optimized	by	infusing	1.00	µg/mL	
neat	solutions	into	mass	spectrometer	in	about	a	100‐500	m/z	
range,	 in	 positive	 polarity	mode	 using	 electrospray	 ionization	
technique.	 Best	 intensity	 for	 precursor	 ions	 and	 product	 ions	
was	found	in	the	positive	mode	for	both	drugs	as	they	have	the	
ability	 to	accept	protons.	The	protonated	molecular	 ions	 [M	+	
H]+	of	TAM,	FIN	and	IS,	observed	on	the	full	scan	mass	spectra,	
were	408.74,	373.11	and	255.75	m/z,	respectively.	
Moreover,	 the	 collision	 energy	 in	Q2	 produced	 significant	
fragments.	 The	MS/MS	 transition	408.74	→	227.29,	 373.11	→	
304.96	and	255.75	→	166.15	for	TAM,	FIN	and	IS,	respectively,	
were	selected	since	 these	products	 ions	 represented	 the	most	
abundant	 ions	 by	 applying	 sufficient	 collision	 activated	
dissociation	gas	and	collision	energy	(Figure	2).	Optimization	of	
capillary	temperature	and	sheath	gas	flow	is	important	as	they	
play	a	great	role	in	minimizing	ion	suppression	and	altering	the	
sensitivity.	Adjustment	of	capillary	 temperature	at	270	°C	and	
sheath	 gas	 at	 20	psi,	 augmented	 the	 intensity	 of	 the	 analytes.	
Minor	changes	in	ion	spray	voltage	did	not	have	a	marked	effect	
on	the	signal	intensity	and	was	maintained	at	3600	V.	
	
	(a)	
(b)
	(c)	
	
Figure	2.	Product	ion	spectra	of	[M	+	H]+	of	TAM	(a),	FIN	(b)	and	IS	(c).
	
To	 obtain	 the	 best	 chromatographic	 separation	 with	 the	
desired	response	it	was	observed	that,	mobile	phase	as	well	as	
selection	of	column	is	an	important	criterion.	Chromatographic	
analysis	 of	 the	 drugs	 and	 IS	 was	 initiated	 under	 isocratic	
conditions	with	the	aim	to	develop	a	simple	separation	process	
with	 a	 short	 run	 time.	 Separation	 was	 tried	 using	 various	
combination	 of	 acetonitrile	 and	 buffer	 solution	 with	 varying	
contents	of	each	component	on	different	columns	like	Hypersil‐
Gold	 (C18‐bonded	 ultrapure	 silica	 based	 column)	 and	 Bio	
Basic‐8	to	identify	the	optimal	conditions	that	produce	the	best	
sensitivity,	efficiency	and	peak	shape.	The	use	of	buffer	solution	
helped	 in	achieving	good	response	 for	MS	detection	operating	
in	the	positive	mode.	Thus,	a	mobile	phase	consisting	of	10	mM	
ammonium	 acetate	 buffer	 pH	 adjusted	 to	 3.5	 with	 acetic	
acid:acetonitrile	 (10:90,	 v:v)	 was	 found	 suitable	 as	 the	 drugs	
were	protonated	 and	well	 separated	by	 this	phase	 (Figure	3).	
High	content	of	acetonitrile	(90%)	in	the	mobile	phase	helped	
in	eluting	the	drugs	along	with	their	 IS	within	3	min	at	a	 flow	
rate	of	250	µL/min.	Hypersil‐Gold	(50.0	mm	×	2.0	mm,	1.9	µm	
particle	size)	column	gave	good	peak	shape	and	response	even	
at	LOQ	levels	for	both	drugs.		
	
	
Figure	3. Representative	SRM	chromatograms	of	IS	(40	ng/mL)	(a),	FIN	(300	
ng/mL)	(b)	and	TAM	(25	ng/mL)	(c).	
	
	
3.1.	Method	validation	
	
3.1.1.	Linearity	and	range	
	
Under	 the	 optimum	 chromatographic	 and	 mass	
spectrometric	conditions	a	linear	relationship	was	established.	
The	calibration	graphs	were	found	to	be	rectilinear	within	the	
concentration	range	of	1.6‐40.0	ng/mL	for	TAM	and	20.0‐500.0	
ng/mL	 for	 FIN.	 The	 linearity	 of	 standard	 curves	 (r2)	 for	 all	
analytes	 were	 greater	 than	 0.99.	 The	 calibration	 curve	 had	 a	
reliable	 reproducibility	 across	 the	 calibration	 range.	 The	
corresponding	regression	equations	are	cited	in	Table	2,	where	
the	slopes	are	consistent	with	the	relative	peak	areas.	
	
3.1.2.	Accuracy	and	precision	
	
The	 accuracy	 of	 the	 proposed	 method	 was	 evaluated	 by	
analyzing	six	levels	of	standard	solutions	of	the	studied	drugs,	
each	three	times.	The	results	obtained	by	the	proposed	method	
were	favorably	compared	with	those	of	reference	ones	[26]	for	
TAM	and	[5]	for	FIN.		
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Table	2.	Performance	data	for	tamsulosin	and	finasteride	by	the	proposed	LC‐MS/MS	method	*.	
Parameter	 Tamsulosin	 Finasteride 
Linearity	range	 1.60	‐ 40.00	ng/mL 20.00	‐ 500.00	ng/mL	
Regression	equation	 7.21×10‐3	C	‐ 1.82×10‐3 1.85×10‐4 C	‐ 6.56×10‐3	
Slope	(b)	 7.21×10‐3	 1.85×10‐4	
Intercept	(a) 1.82×10‐3	 6.56×10‐3	
Correlation	coefficient	(r)	 0.9998	 0.9997	
R2	 0.9997	 0.9995	
SE	of	slope	 6.45×10‐5 2.12×10‐6
SE	of	intercept	 1.42×10‐3 5.84×10‐4
Sy/x	 2.11×10‐3 8.67×10‐4
LOD	 0.50	ng/mL 5.00	ng/mL
LOQ	 1.60	ng/mL 20.00	ng/mL
*	C:	Concentration,	Sy/x:	Standard	deviation	of	residuals,	LOD:	Limit	of	detection,	LOQ:	Limit	of	quantification.	
	
	
Table	3.	Accuracy	and	precision	data	obtained	by	the	proposed	LC‐MS/MS	method	and	the	reference	ones	for	the	analysis	of	tamsulosin	and	finasteride	in	pure	
form	a.		
Item	 Tamsulosin	 Finasteride 
Proposed	 Reported	[26]	c Proposed Reported	[5]	d	
Mean	b	±	SD	 100.11±0.78	 99.54±0.88 100.01±0.61 99.86±0.81	
%	RSD	 0.78	 0.88 0.69 0.81	
%	REr	 0.32	 0.44 0.28 0.40	
n	 6	 4 6 4	
Variance	 0.61	 0.77 0.47 0.65	
t‐	test	(2.31)	 1.08	 0.32 	
F‐	test	(5.409)	 1.26	 	 1.37	 	
Intraday	precision	b	 99.83±0.77	 99.75±0.63 	
Inter‐day	precision	b		 99.16±0.83	 	 99.06±1.01	 	
a	SD:	Standard	deviation,	%RSD:	Percent	relative	standard	deviation,	%REr:	Percent	relative	standard	error,	Values	in	parenthesis	are	the	theoretical	values	of	t	
and	F	at	p	=	0.05	[28].	
b	Average	of	three	different	determinations.	
c	 The	 reported	method	 for	 tamsulosin	 [26]	 is	 an	HPLC	method	 and	was	 performed	 using	 	 C18	Column	250	 ×	4.6	mm	 (particle	 size	 of	5	 µm).	Mobile	 phase:	
acetonitrile:	(0.05	M)	KH2PO4	buffer	(45:55)	at	flow	rate	1.8	mL/min.	The	detection	was	monitored	at	240	nm.		
d	The	official	method	for	finasteride	[5]	is	an	HPLC	method	and	was	performed	using	,	C18	Column.	Mobile	phase,	water:tetrahydrofuran	(4:1,	v:v).	The	detection	
was	monitored	at	215	nm.	
	
	
Table	4.	Determination	of	tamsulosin	and	finasteride	in	laboratory	prepared	mixtures	by	the	proposed	LC‐MS\MS	method.	
Concentration	(ng/mL)	 %	Recovery	* 	
Tamsulosin	 Finasteride	 Tamsulosin	 Finasteride	
30.00	 30.00	 101.04 97.95	
30.00	 60.00	 100.45 98.06	
40.00	 20.00	 99.76	 99.95	
10.00	 125.00	 100.35	 99.55	
30.00	 375.00	 98.76 100.09	
20.00	 200.00	 100.59	 98.50	
Mean	±	SD	 100.16±0.80 99.02±0.96	
%	RSD	 0.80	 0.97	
%	Rer	 0.33	 0.40	
Variance	 0.64	 0.93	
*	Average	of	three	different	determinations.	
	
	
	
Statistical	 analysis	 [28]	 obtained	 by	 the	 proposed	 and	
reported	methods	 using	 student´s	 t‐test	 and	 variance	 ratio	 F‐
test,	showed	no	significant	difference	between	the	performance	
of	 the	 two	 methods	 regarding	 the	 accuracy	 and	 precision,	
respectively,	(Table	3).		
In	 addition,	 the	 intraday	 precision	was	 evaluated	 through	
replicate	 analysis	 of	 the	 standard	 solutions	 of	 the	 drugs.	
However,	 the	 interday	 precision	 was	 performed	 through	
replicate	 analysis	 of	 the	 standard	 solutions	 of	 the	 drugs	 on	
three	successive	days.	The	percentage	recoveries	as	well	as	the	
percentage	 relative	 standard	 deviations	 were	 calculated	 as	
abridged	in	Table	3.	The	repeatability	of	the	proposed	method	
is	good	as	indicated	by	small	value	of	standard	deviation	(SD).	
	
3.1.3.	Limit	of	detection	(LOD)	and	limit	of	quantification	
(LOQ)	
	
The	 limit	 of	 quantification	 (LOQ)	 was	 determined	 by	
establishing	 the	 lowest	 concentration	 that	 can	 be	 measured	
according	 to	 USP	 34	 recommendations,	 below	 which	 the	
calibration	graph	 is	nonlinear	and	was	 found	to	be	1.6	ng/mL	
for	TAM	and	20.0	ng/mL	for	FIN.	The	limit	of	detection	(LOD)	
was	determined	by	evaluating	the	 lowest	concentration	of	 the	
analyte	 that	 can	 be	 readily	 detected	 and	was	 found	 to	 be	 0.5	
ng/mL	for	TAM	and	5.0	ng/mL	for	FIN.	
	
3.1.4.	Robustness	of	the	method	
	
The	 robustness	of	 the	method	adopted	was	demonstrated	
by	 the	 consistency	 of	 the	 relative	 peak	 area	 values	 with	 the	
deliberately	minor	 changes	 in	 the	 chromatographic	 and	mass	
spectrometric	parameters,	e.g.	 the	pH	of	 the	buffer	 (±0.5),	 the	
turbo	 ion	spray	temperature	or	capillary	 temperature	(±5	°C),	
sheath	gas	flow	(±5	psi)	and	collision	energy	(±5	V).	
	
3.2.	Application	of	the	proposed	method	
	
The	 proposed	 method	 was	 successfully	 applied	 to	 the	
analysis	 of	 TAM	 and	 FIN	 in	 laboratory	 prepared	 mixtures	
containing	both	drugs	 in	different	 ratios.	The	average	percent	
recoveries	 were	 based	 on	 the	 average	 of	 three	 replicate	
determinations	(Table	4). 
To	 indicate	 the	 potential	 of	 LC‐MS	 for	 quality	 control	 and	
routine	 analysis	 of	 TAM	 and	 FIN	 in	 pharmaceutical	
formulation;	Urimax	F	tablets	were	analyzed.		
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Table	5.	Application	of	standard	addition	technique	for	the	determination	of	tamsulosin	and	finasteride	in	pharmaceutical	formulation	a.	
Item	 Taken	concentration	(ng/mL)	 Added	concentration	(ng/mL)	 %	Recovery	b	
Tamsulosin	 Finasteride	 Tamsulosin Finasteride Tamsulosin	 Finasteride
5.00	 62.50	 5.00	 62.50	 99.95	 98.89	
5.00	 62.50	 10.00	 125.00	 99.99	 98.54	
5.00	 62.50	 15.00 187.50 98.16 98.24	
5.00	 62.50	 20.00 250.00 99.00 97.98	
5.00	 62.50	 25.00 312.50 98.85 99.69	
5.00																																	62.50	 30.00 375.00 98.05 97.00	
Mean	±	SD	 98.76±0.78	 98.12±0.89	 	 	 99.00±0.84	 98.39±0.90	
%	RSD	 0.79	 0.91	 0.85 0.92	
%	Rer	 0.32	 0.37	 0.35 0.37	
Variance	 0.61	 0.79	 0.70 0.82	
a	SD:	Standard	deviation,	%RSD:	Percent	relative	standard	deviation,	%REr:	Percent	relative	standard	error.	
b	Average	of	three	different	determinations.	
	
	
	
The	 concentrations	 of	 the	drugs	were	 calculated	 referring	
to	 the	 corresponding	 regression	 equation.	 The	 coupling	 of	 LC	
with	 MS/MS	 detection	 in	 the	 SRM	 mode	 showed	 high	
specificity,	because	only	 the	 ions	derived	 from	 the	analytes	of	
interest	 were	 monitored,	 thus,	 commonly	 used	 tablet	
excipients	did	not	 interfere	 in	 the	analysis	as	 indicated	by	the	
percentages	 found.	 The	 results	 obtained	 by	 applying	 the	
standard	addition	technique	are	abridged	in	Table	5.	
	
4.	Conclusion	
	
A	 rapid	 and	 precise	 liquid	 chromatography	 with	
electrospray	ionization	tandem	mass	spectrometry	method	for	
the	 determination	 of	 tamsulosin	 and	 finasteride	 in	 bulk	
powders	 and	 in	 pharmaceutical	 formulation	 was	 developed	
and	 validated.	 The	method	 offers	 several	 advantages	 such	 as	
unnecessary	 complete	 separation	 of	 analytes,	 non‐tedious	
sample	 preparation.	 In	 addition,	 the	 short	 run	 time	 and	 the	
relatively	low	flow	rate	allows	the	analysis	of	a	large	number	of	
samples	with	less	mobile	phase	that	proves	to	be	cost	effective.	
The	 data	 validation	 shows	 that	 the	 optimized	 LC‐MS/MS	
possess	specificity,	sensitivity,	linearity,	precision	and	accuracy,	
thus,	the	proposed	method	can	be	used	for	the	routine	analysis	
of	tamsulosin	and	finasteride	in	pharmaceutical	dosage	forms.	
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